Pharmaceuticals

Colorcon Celebrates Grand Opening of New Manufacturing Facility in Malaysia

Johor plant is Colorcon's 7th major film coating plant and 16th manufacturing facility worldwide HARLEYSVILLE, Pa. and JOHOR, Malaysia, July 24, 2025 /PRNewswire/ -- Colorcon, a global leader of film coating systems, specialty excipients, controlled release formulations and controlled atmosphere...

2025-07-24 22:00 3037

AMSC Malaysia 2025 Set to Spotlight World-Class Expertise and Innovation in Aesthetic Medicine and Surgery

KUALA LUMPUR, Malaysia, July 24, 2025 /PRNewswire/ -- The Aesthetic Medicine & Surgery Conference & Exhibition (AMSC)  returns for its fourth edition fromAugust 6-7, 2025, with an expanded focus on global participation and advanced education. Held at theKuala Lumpur Conv...

2025-07-24 20:24 4007

Seegene unveils the world's first unattended PCR automation, igniting a global diagnostic paradigm shift at ADLM 2025

* Fully Unmanned— CURECA™, the 100% Automated Diagnostic System Defining the Future Gold Standard, Debuts inChicago, July 28–31 * Unifying global diagnostic data - STAgora™, the big data platform set to transform the future of diagnostics * Offering early access to the new diagnostic parad...

2025-07-24 17:36 2510

Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer

HONG KONG, July 23, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been enrolled in the pivotal/registration Phase III clinical trial (AK112-310/HARMONi-GI2) of ivonescimab, a first-in-class PD-1/VEGF bispecific antibody dev...

2025-07-24 09:14 1505

HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma

* Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma, with an initial data readout expected in mid-2026 * HBM9378/WIN378 has the potential to be the first-to-market long-acting anti-TSLP antibody with twice-yearly dosing for asthma ...

2025-07-23 20:36 2220

Samsung Biologics reports second quarter 2025 financial results

* Recorded Q2'25 consolidated revenue of KRW 1,289.9 billion * Recorded Q2'25 consolidated operating profit of KRW 475.6 billion * Solid momentum sustained through capacity ramp-up and stable project execution INCHEON, South Korea, July 23, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940...

2025-07-23 14:54 2228

Telix Reports $204M Revenue, Up 63% YOY

MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise. ...

2025-07-22 16:02 2603

METiS Technologies Showcases AI-Powered Nanodelivery Platform at the 2025 Controlled Release Society Annual Meeting

HANGZHOU, BEIJING, China and CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the presentation of its latest research findings at the poster session of the 2025 Controlled Release Society (CRS) Annual Meeting...

2025-07-22 15:52 2535

DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation

SHANGHAI, July 21, 2025 /PRNewswire/ -- DualityBio (HKEX Stock Code: 9606.HK) announced thatthe U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting antibody-drug conjugate (ADC) DB-1310. This designation is for the treatment of ad...

2025-07-22 10:25 2301

Precision Era to Redefine Treatment, Drive $450B Economic Investment and Change Lives Across Asia Pacific

SINGAPORE, July 22, 2025 /PRNewswire/ -- The Precision Era of medicine is arriving inAsia Pacific, driven by the arrival of a critical mass of innovative therapies that will redefine treatment, attract investment and improve lives, a new expert-driven report finds. Released today, 'On the Cusp o...

2025-07-22 10:07 2862

Bloomage Achieves FDA GMP Audit with Zero-Deficiency, Reinforcing Global Trust

PARSIPPANY, N.J., July 21, 2025 /PRNewswire/ -- Bloomage, a global leader in hyaluronic acid and other bioactive substance innovations, has announced it successfully passed the U.S. Food and Drug Administration (FDA)'s on-site GMP audit with a "No Action Indicated" (NAI) result. This is the best ...

2025-07-21 21:00 1640

CPHI & PMEC Shenzhen 2025: Unlocking New Opportunities in Asia and the Greater Bay Area

SHANGHAI, July 21, 2025 /PRNewswire/ -- CPHI & PMEC China 2025 concluded in June with a record-breaking 109,056 attendees, underscoring strong demand within China's thriving pharma industry.  Building on this success, CPHI & PMEC Shenzhen 2025  will tak...

2025-07-21 14:31 2238

CorestemChemon Expands Global CRO Reach with ATG Lifetech, Targeting Next-Gen Preclinical Services

Strategic partnership to deliver transcriptomics-powered, organoid-based preclinical testing for high-impact drug discovery  SEOUL, South Korea, July 20, 2025 /PRNewswire/ -- CorestemChemon, a leading GLP-certified preclinical CRO based inSouth Korea, has entered into a strategic partnership wit...

2025-07-21 10:54 1714

Co-PSMA trial: Recruitment successfully completed

SYDNEY, July 17, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT...

2025-07-17 21:01 2294

SK bioscience Submits IND for Phase 1/2 Clinical Trial of Adjuvanted Influenza Vaccine Candidate

* Company aims for technology advancement and platform expansion with Korea's first influenza vaccine using an adjuvant * Interim results from the Phase 1/2 trial expected by 2027, aimed at entering the high-immunogenicity vaccine market * "Our SKYCellflu platform with our adjuvanted vaccine...

2025-07-17 19:00 2102

Five-year Pharmacovigilance study by NTC confirms safety of fixed-dose eye drops for Post-cataract Surgery

MILAN, July 17, 2025 /PRNewswire/ -- A recently published five-year pharmacovigilance study confirms the excellent safety profile of a fixed-dose combination eye drop containing ananti-inflammatory steroid and a quinolone antibiotic, developed by NTC, indicated for the prevention and treatment of...

2025-07-17 17:00 2010

GC Biopharma Receives Marketing Authorization for BARYCELA in Vietnam

YONGIN, South Korea, July 17, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean pharmaceutical company, announced that its varicella vaccine BARYCELA has received marketing authorization from the Drug Administration of Vietnam (DAV). Following domestic approval in 2020 and WHO Pre-Q...

2025-07-17 13:56 1687

Total Investment of Approx. USD 7.3 Million in Malaria and TB R&D Projects With Partners Including European Vaccine Initiative, University of Copenhagen, and University of Tübingen

TOKYO, July 17, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximatelyJPY 1 billion ( USD 7.3 million1) in four R&D projects for the development of vaccine, drug, and diagnostics for malaria and tuberculosis (TB).2 Investment o...

2025-07-17 10:00 1959

Unlocking New Opportunities in Asia and the Greater Bay Area

SHANGHAI, July 16, 2025 /PRNewswire/ -- CPHI & PMEC China 2025 concluded in June with a record-breaking 109,056 attendees, fostering meaningful connections across the entire pharmaceutical supply chain. This remarkable success is a testament to the strong demand withinChina's thriving pharma indu...

2025-07-17 09:55 1506

Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2025-07-17 08:00 2312
1 ... 31323334353637 ... 339

Week's Top Stories